Open AccessSafety and Efficacy of Therapeutically Equivalent Doses of Sustained‐Release Formulations of Isradipine and Felodipine
Author(s) -
Ganz Michael B.,
Saksa Brett A.
Publication year - 2003
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1527-5299.2003.03252.x
Subject(s) - isradipine , felodipine , medicine , blood pressure , adverse effect , diastole , anesthesia , pharmacology , antagonist , receptor
This open‐label, drug substitution study was conducted to determine if subjects receiving sustained‐release isradipine (SR‐I) can be safely switched to sustained‐release felodipine (SR‐F) and to assess whether SR‐I provides better 24‐hour blood pressure (BP) control than SR‐F. Forty‐one men receiving either SR‐F 5 mg or SR‐F 10 mg once daily for at least 6 months were switched to an equivalent dose of SR‐I; BP was measured 2, 4, and 6 weeks after substitution. Significant reductions in systolic BP were seen in the SR‐I 10 mg group after 4 weeks and they remained significantly lower through 6 weeks ( p≤ 0.05). Diastolic BP was reduced, but not significantly. After 6 weeks, SR‐F therapy was reinstated, and BP returned toward baseline values. No serious adverse events were reported. SR‐I can be safely substituted for SR‐F and may provide better 24‐hour control of BP than SR‐F.